NTRBHealthcare · BiotechnologyNTRB Stock Forecast: Nutriband, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Nutriband, Inc. hold a median 12-month price target of $15 — +433.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
NTRB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Nutriband, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (8): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Nutriband, Inc. — and when they’d sell — is the membership.
NTRB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NTRB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +433.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Jan 2025 | Noble Capital Markets | Initiates | Outperform | $13 |
| 26 July 2022 | Small Cap Consumer Research | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NTRB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Nutriband, Inc. (NTRB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.1×
- Price / sales
- 19.2×
- Price / book
- 5.8×
- EV / EBITDA
- −3.9×
Cheaper than 82% of US stocks
Cheaper than 9% of US stocks
Cheaper than 18% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- −35.1%
- Earnings growth (YoY)
- −35.1%
- Gross margin
- 45.4%
- Operating margin
- −289.4%
- Net margin
- 27.8%
Higher than 8% of US stocks
Higher than 14% of US stocks
Higher than 58% of US stocks
Higher than 10% of US stocks
Higher than 87% of US stocks
- Return on equity
- −145.7%
- Return on assets
- −78.2%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NTRB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTRB appears on the weeks it earns a place.
Frequently asked questions about NTRB stock
What is the NTRB stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Nutriband, Inc. have a median 12-month price target of $15, with estimates ranging from $15 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NTRB stock a buy right now?
Of the 1 analysts covering Nutriband, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nutriband, Inc. 17 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NTRB?
As at 1 Aug 2026, Nutriband, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).
Will NTRB stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +433.8% from the last close, and Ticker Nerd's factor model ranks Nutriband, Inc. 17 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NTRB stock forecast for 2030?
No analyst covering Nutriband, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $15 over the next 12 months.
How has NTRB stock performed over the past year?
Nutriband, Inc. returned -62.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Nutriband, Inc. do?
Nutriband Inc. is a pharmaceutical and healthcare company specializing in the development and commercialization of transdermal products and technologies.
About Nutriband, Inc.
Nutriband Inc. is a pharmaceutical and healthcare company specializing in the development and commercialization of transdermal products and technologies. The primary focus of Nutriband is to improve the safety and efficacy of drug delivery systems. By leveraging transdermal adhesive materials, Nutriband Inc. offers an innovative approach to drug administration that bypasses the gastrointestinal tract and liver, enabling a more direct and controlled delivery to the bloodstream. This approach can reduce side effects and improve patient compliance. Nutriband's technologies have broader applications not only in delivering medications effectively but also in enhancing safety in medical treatments, which is critical across pharmaceutical and biotechnology industries. With its commitment to therapeutic advancements, Nutriband Inc. plays an essential role in the ongoing transformation of drug delivery systems, potentially impacting a variety of treatment areas and improving patients' experiences across different healthcare settings.
CEO Mr. Gareth Sheridan · United States · https://www.nutriband.com